Stay updated on OPUS Clinical Trial: Natalizumab in Focal Epilepsy
Sign up to get notified when there's something new on the OPUS Clinical Trial: Natalizumab in Focal Epilepsy page.

Latest updates to the OPUS Clinical Trial: Natalizumab in Focal Epilepsy page
- Check6 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 was removed.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now displays Revision: v3.4.2 instead of v3.4.1; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision: v3.4.1 appears to replace the prior v3.4.0 without altering core study content or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check49 days agoChange DetectedThe update adds a 'Show glossary' feature and a footer label 'Revision: v3.4.0', and includes small wording/capitalization tweaks such as 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check63 days agoChange DetectedThe page now shows Revision: v3.3.4, replacing v3.3.3, with no changes to study details or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check84 days agoChange DetectedAdded a comprehensive Locations section listing all study sites by state (Alabama, Arizona, California, District of Columbia, Florida, Hawaii, Illinois, Maryland, Massachusetts, Michigan, Missouri, New Jersey, New York, North Carolina, Ohio, Pennsylvania, South Carolina, Texas, Washington) and updated the revision tag from v3.3.2 to v3.3.3.SummaryDifference2%

Stay in the know with updates to OPUS Clinical Trial: Natalizumab in Focal Epilepsy
Enter your email address, and we'll notify you when there's something new on the OPUS Clinical Trial: Natalizumab in Focal Epilepsy page.